MGRX · Mangoceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.9K | - | $84.2K | $168.1K | $109.3K | - | $133.4K | $163.2K | $214.1K | - |
| Cost of Revenue | $8.2K | - | $2.4K | $18.8K | $24.7K | - | $21.5K | $29.7K | $20.8K | - |
| Gross Profit | $29.0K | - | $50.9K | $89.9K | $62.1K | - | $82.7K | $69.8K | $147.4K | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $1.05M | - | $311.4K | $1.25M | $1.54M | - | $523.9K | $850.7K | $772.0K | - |
| Total Operating Expenses | $3.16M | - | $7.59M | $5.36M | $4.92M | - | $1.84M | $2.24M | $2.52M | - |
| D&A | $250 | - | - | - | $6.2K | - | - | - | $6.2K | - |
| Operating Income | ($3.13M) | - | ($7.54M) | ($5.27M) | ($4.85M) | - | ($1.76M) | ($2.17M) | ($2.37M) | - |
| Interest Expense | - | - | $75.8K | $21.7K | ($13.7K) | - | - | - | $1.8K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.40M) | - | ($7.62M) | ($5.42M) | ($4.84M) | - | ($2.00M) | ($2.39M) | ($2.37M) | - |
| EPS - Basic | ($0.22) | - | ($0.69) | ($0.57) | ($1.29) | - | ($0.99) | ($1.35) | ($1.50) | - |
| EPS - Diluted | ($0.22) | - | ($0.69) | ($0.57) | ($1.29) | - | ($0.99) | ($1.35) | ($1.50) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $174.6K | $1.49M | $481.3K | $101.0K | $76.5K | $58.7K | $73.9K | $490.2K | $15.3K | $739.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | $13.2K | $14.0K | $14.5K | $18.5K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $212.5K | $1.55M | $598.2K | $118.0K | $176.7K | $75.6K | $104.1K | $517.6K | $89.8K | $818.5K |
| Total Assets | $14.45M | $16.09M | $16.53M | $20.84M | $21.75M | $15.37M | $14.79M | $15.24M | $301.4K | $1.05M |
| Current Liabilities | $737.6K | $890.6K | $804.3K | $1.60M | $1.50M | $1.43M | $1.39M | $1.38M | $1.21M | $211.1K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $974.6K | $890.6K | $804.3K | $1.60M | $1.50M | $1.43M | $1.40M | $1.41M | $1.26M | $276.0K |
| Stockholders' Equity | $13.48M | $15.20M | $15.73M | $19.24M | $20.25M | $13.95M | $13.39M | $13.83M | ($958.4K) | $774.8K |
| Retained Earnings | ($44.05M) | ($40.65M) | ($37.88M) | ($31.65M) | ($25.94M) | ($20.81M) | ($17.99M) | ($15.99M) | ($13.60M) | ($11.23M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.31M) | - | - | - | ($2.27M) | - | - | - | ($991.1K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | $2.29M | - | - | - | $267.5K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 42.7% | - | 60.4% | 53.5% | 56.8% | - | 62.0% | 42.8% | 68.8% | - |
| Operating margin | -4606.8% | - | -8953.5% | -3134.0% | -4440.0% | - | -1318.2% | -1329.1% | -1105.9% | - |
| EBITDA margin | -4606.4% | - | - | - | -4434.3% | - | - | - | -1103.0% | - |
| Net margin | -5014.7% | - | -9042.8% | -3221.6% | -4427.4% | - | -1499.0% | -1465.4% | -1105.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 1553.3% | - | 369.6% | 740.8% | 1411.1% | - | 392.8% | 521.4% | 360.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.6% | - | -46.1% | -26.0% | -22.2% | - | -13.5% | -15.7% | -785.4% | - |
| Return on equity | -25.3% | - | -48.4% | -28.1% | -23.9% | - | -14.9% | -17.3% | 247.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.29 | 1.74 | 0.74 | 0.07 | 0.12 | 0.05 | 0.07 | 0.38 | 0.07 | 3.88 |
| Quick ratio | 0.29 | 1.74 | 0.74 | 0.07 | 0.12 | 0.05 | 0.07 | 0.37 | 0.06 | 3.79 |
| Cash ratio | 0.24 | 1.67 | 0.60 | 0.06 | 0.05 | 0.04 | 0.05 | 0.36 | 0.01 | 3.50 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -99.4x | -242.8x | 354.2x | - | - | - | -1345.2x | - |
| Equity multiplier | 1.07 | 1.06 | 1.05 | 1.08 | 1.07 | 1.10 | 1.10 | 1.10 | -0.31 | 1.36 |
| Liabilities / Assets | 0.07 | 0.06 | 0.05 | 0.08 | 0.07 | 0.09 | 0.09 | 0.09 | 4.18 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.01 | 0.01 | - | 0.01 | 0.01 | 0.71 | - |
| Inventory turnover | - | - | - | - | - | - | 1.63 | 2.12 | 1.44 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | 224d | 172d | 254d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | - | 1.6x | 0.8x | 0.4x | - | 0.5x | 8.6x | - | - |
| P / S | 87.4x | - | 299.6x | 90.3x | 81.9x | - | 53.5x | 729.4x | 347.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -37.9% | - | -36.8% | 3.0% | -48.9% | - | -45.6% | 15.5% | 112.6% | - |
| Revenue CAGR (3y) | -12.3% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -53.3% | - | -38.4% | 28.9% | -57.9% | - | -42.8% | -19.9% | 157.7% | - |
| Operating income growth (YoY) | 35.6% | - | -329.0% | -142.9% | -105.0% | - | 2.3% | 5.4% | 7.5% | - |
| Net income growth (YoY) | 29.7% | - | -281.1% | -126.5% | -104.4% | - | -11.1% | -4.7% | 7.5% | - |
| EPS growth (YoY) | 82.9% | - | 30.3% | 57.8% | 14.0% | - | -800.0% | -864.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -33.5% | 9.0% | 17.5% | 39.1% | - | 1700.1% | 1525.8% | 360.6% | - | - |
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing MANGOCEUTICALS against the 5 most active filers in the same SIC group.